1. Introduction {#sec1}
===============

Uterine cervical cancer is still the most commonly diagnosed cancer among women worldwide, taking second place only after breast cancer \[[@B1]--[@B4]\]. The incidence and mortality from cervical cancer decreased considerably in most industrial countries due to lower incidence and the introduction of screening \[[@B5], [@B6]\]. On the other hand, malignant or precancerous lesions of glandular cells in uterine cervix are increasing recently, as reported that the incidence of adenocarcinoma of Japan is 16.8% in 2009, and many studies reported higher mortality rate of cervical adenocarcinoma \[[@B7]--[@B12]\]. The screenings of the glandular lesions are thought to be difficult in comparison with those of the squamous epithelium type, although those early diagnoses become more important for prognosis improvement.

In late years, Japan Association of Obstetricians and Gynecologists announced a standardized system of terminology reflected by the Bethesda system (TBS) and the screening of cervical lesions are being performed based on this system \[[@B13]\]. In this new Japanese system, increasing numbers of facilities come to use LBC, which is a global tendency, despite the premise to use conventional smears for sampling. In many reports of the comparison studies between LBC and conventional smear with clinical and histological followups, LBC is better than conventional smear in detecting biopsy-proven disease and in screening out benign abnormalities in terms of squamous lesions \[[@B14]--[@B22]\]. However, it still remains unclear how to evaluate the cytological diagnosis of the glandular lesion in the new system using LBC.

We recently started TBS application using both of conventional smears and the liquid-based cytology as a multicenter study which simultaneously investigates HPV infection. In this study, we examined the correlation between conventional smears and LBC in the cytological diagnosis of the glandular lesion in order to make it clear whether LBC has the diagnosis precision that is equivalent to conventional smear.

2. Materials and Methods {#sec2}
========================

At eight institutions in Hiroshima prefecture, including the key institution, National Hospital Organization, Japan, and Kure Medical Center/Chugoku Cancer Center (NHOKMCCCC), from November 2007 to July 2009, 4522 cases were retrieved and analyzed as split-sample studies. Initially, smears were taken in the routine fashion using EndoCervex-Brush (Rovers Medical Devices B. V., Oss, The Netherlands) in each institution, fixed either by immersion in 95% ethanol or by spray fixation with a pump-action spray, and preserved before staining (conventional smear, CS). The residual cells remaining on the sampler were rinsed into vials containing 20 mL of preservative, then, sent to the key institution, followed by the treatment according to the ThinPrep (Hologic, Marlboruogh, Mass, USA) protocol (ThinPrep, TP). An additional sample was obtained with a dacron swab and placed in specimen transport medium (STM) for future human papillomavirus (HPV) DNA testing. Specimens prepared by each method underwent Papanicolaou staining and was enclosed.

The specimens are initially screened by cytotechnologists in the manner of TBS. The screening was performed as blinded experiment, namely, each specimen by the CS or TP method was diagnosed by the other screener, which did not know the information by the other methods nor HPV data. Possibly abnormal specimens are referred to senior cytotechnologists and cytopathologists for review. The specimens diagnosed as abnormal in each institution were shipped to the key institution to be reviewed by the central committee, which consists of the senior pathologists, for determining the final cytological diagnosis. Prior to the study, all the cytotechnologists and the cytopathologists were engaged in this study who trained in the use of TBS and acquired the certification of ThinPrep test presided over in Cytyc Co. (Marlborough, Mass).

Histological examination was also performed in some cases following the cytology or after few periods, if required for clinical reason. The histological diagnosis was made by pathologist independently from cytology. In all the cases other than NILM, which were diagnosed by either CS and/or TP method, cancer-associated 16 HPV genotyping (types 16, 58, 52, 51, 56, 31, 18, 39, 66, 59, 6, 33, 30, 35, 45, and 11) was performed by multiplex PCR as described previously using the remaining samples in the TP preservative fluid \[[@B23]\]. All the institutions have full reviews and approvals from respective Institutional Review Boards. Statistical analyses were performed in the key institution. Photographs of cytology by CS and TP as well as histological ones were displayed in representative cases.

3. Results {#sec3}
==========

We initially performed analysis in all the lesions of the samples, including squamous ones, prior to the analysis specific for glandular lesions. The cytological diagnosis in TBS by CS or TP method in all the 4522 cases is shown in [Table 1](#tab1){ref-type="table"}. The average age of the patients was 46.1. Patients who consulted due to medical checkup were 13.8% and those who had any complaints were 89.3%. The number of cases which diagnosed positive was 460 (10.2%) by CS and 403 (8.9%) by TP. Cytologically positive cases by each method were categorized as follows: 49 cases of ASC (1.1%), 5 cases of AGC (0.11%), 73 cases of LSIL (1.7%), 5 cases of HSIL (0.11%), 1 case of SCC (0.02%), 1 case of ADC (0.02%) in CS, 36 cases of ASC (0.8%), 1 cases of AGC (0.02%), 33 cases of LSIL (0.7%), and 7 cases of HSIL (0.15%), neither cases of SCC nor ADC in TP were reparted. There was no large variation of distribution of each category in each method. The diagnoses by TP and CS corresponded with each other in 4198 cases (92.8%).

Discrepancies in the diagnosis between CS and TP were shown in Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}. There were 7 cases in which TP method revealed HSIL and more, and CS was negative, as well as 7 cases in whom HSIL and more were detected with CS alone. All the other cases diagnosed as positive, either TP or CS alone, were 77 and 134, respectively. In the comparison between CS and TP methods of all the cases, 127 (2.8%) were up-graded by TP and 185 (4.1%) were up-graded by CS. Within the limits of HSIL, FSFI, and SCC/SDC up-grading was observed in 45 (1.0%) cases by TP and in 41 (0.9%) cases in CS.

[Table 4](#tab4){ref-type="table"} presents the glandular abnormalities detected by either TP or CS. Thirteen cases were reported with either AGC or adenocarcinoma, including 12 cases diagnosed by CS and eight cases by TP. Seven cases were diagnosed as either AGC or adenocarcinoma by both CS and TP methods. Among eight cases which were diagnosed as AGC by CS, four were NILM, one was ASC-US, and two were AGC by TP. Similarly, three cases were diagnosed AGC and one case was adenocarcinoma by TP out of four cases which were adenocarcinoma by TP. Thus, this shows that the diagnosis by TP tends to be milder than that by CS in terms of glandular abnormalities. Histological final diagnoses were obtained from either surgical or biopsy samples in eight cases; one benign, two hyperplasic, and five malignant glandular lesions in the 12 cases. There is also one additional case in which glandular abnormality was suspected due to the presence of HPV infection. TP identified six (66.7%) cases as either AGC or adenocarcinoma in these nine cases presenting glandular abnormality, as CS did all nine cases. With regard to screening for glandular abnormalities, the credibility of TP method is considered to be near to that of CS. Representative microscopic field of cytological samples from CS or TP method are exhibited in Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}.

4. Discussion {#sec4}
=============

LBC preparation was approved for use originally in the United States in 1996, reported to reduce the number of false-positive and false-negative smear results by the reason of overcoming several drawbacks in conventional Papanicolaou smear samples \[[@B22]\]. Also, it is one of the large advantages of LBC that remaining specimen can be used for the additional examination like HPV genotyping. In Japan, conventional smear had been used for the screening until recently, but many institutions have begun LBC in combination to TBS and HPV DNA testing for past a few years. LBC seems to become more and more general method for cervical cancer screening in the future. On the other hand, it is a weak point of LBC that evaluation of glandular abnormalities is not carried out enough. It is reasonable to investigate the capability for diagnosis of glandular abnormalities in cervix, which may become more important disease due to increasing number of the patients.

In this study, there were not so much differences between CS and TP in the detection rate of each category of positive cases. Also, the detection rate of all the positive cases by either CS or TP was similar to that reported previously \[[@B20], [@B21], [@B24]\]. In nine cases analyses, in which AGC or adenocarcinoma were considered by histological examination or HPV infection status, screening as the abnormality to be AGC or more was possible in nine cases by CS and in six cases by TP; thus, CS method seems to be better in the point of accuracy for screening. However, no typical cytological features, which were considered to be cause of oversight, were observed in TP samples. It is confirmed that CS would be equivalent to TP, if only good enough quality of specimen is provided.

On the other hand, the actual numbers of glandular abnormalities are extremely low---only 13 cases in total, with only eight cases with histological followup in this study, including even more than 4000 total cases. These numbers may be low and difficult to perform statistical analysis on, or draw definite conclusions from. The incidence of cervical adenocarcinoma in Japan accounts for 16.8% of whole cervical cancer as described, and this may not correspond to the number of cases of the glandular abnormality having been low in this study. However, in early-stage and the precancerous adenocarcinoma, the cytology is used as adjuvant method in clinical settings, and it seems that the cytological diagnosis rate is lower than a real incidence. Since the numbers limited a thorough statistical analysis and benefits might not provide a true reflection of the value, they were not presented in this study. Also, while it would be appropriate to stratify AGC cases according to the Bethesda Classification, however, in our setting diagnosis of AGC, regardless of the type, would have necessitated further investigations/followup so that patient would not be placed at a disservice as Pap smears is generally considered as a screening modality.

It was thought that the TP method was superior if we considered equalization of the specimen manufacture and additive work (e.g., immunostaining/FISH/HPV DNA test). Therefore, it is important for the screeners to learn the TP and to get enough experience, when it shifts from the CS to TP.

5. Conclusion {#sec5}
=============

In summary, this study extends previous work suggesting that the TP method may become at least as good as CS in detecting glandular lesions, with enough case experience and well mastering the criteria. Considering about the clinical advantages of LBC, it is desirable that TP should be popularized under the enough experience of this method to avoid the confusion about the cytological diagnosis. Based on these results, further larger-scaled studying of this kind would be encouraged to lead more positive conclusions.
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![Case  9. (a) CS method. A small-crowded cluster is comprised of atypical cells, which have relatively distinct nuclei with indented outlines, suggesting AGC. (b) TP method. Marginal number of atypical cells with dense cytosol in small monolayer cluster were diagnosed as ASC-US (Papanicolaou; original magnification, x600, resp.).](PRI2011-743836.001){#fig1}

![Case  12. (a) CS method. A loosely cohesive and crowded tissue fragment displays malignant cells, which have sharp-ended nuclei with enlarged nucleoli, in the myxoid and collagenized matrix, as considered to be adenocarcinoma. (b) TP method. A small number of clusters with irregularly crowded atypical cells are observed in the background, which is clean and devoid of single cells. Since no other such a cluster was observed in the specimen, this case was diagnosed as AGC (Papanicolaou; original magnification, x600, resp.).](PRI2011-743836.002){#fig2}

###### 

Relationship between conventional smear and ThinPrep method.

  -------------------------------------------------------------------------------------------------------------------------------------------------
                        ThinPrep (TP)                                                                                                       
  --------------------- --------------- ---------- -------- ------- --------- -------- ------- ------------ -------- ------- ------- ------ -------
                                        NILM       ASC-US   ASC-H   AGC       LSIL     HSIL    HSILw/FSFI   AIS      SCC     ADC     ADSQ   Total

                                                                                                                                            

  Conventional Smear\   NILM            **3985**   35       1       1         33       7       0            0        0       0       0      4062
  (CS)                                                                                                                                      

  ASC-US                47              **12**     0        0       10        2        0       0            0        0       0       71     

  ASC-H                 2               2          **1**    0       2         1        1       0            0        0       0       9      

  AGC                   5               1          0        **2**   0         0        0       0            0        0       0       8      

  LSIL                  73              17         0        0       **104**   27       0       0            0        0       0       221    

  HSIL                  5               4          0        0       19        **77**   2       0            5        0       0       112    

  HSILw/FSFI            0               0          1        0       0         0        **0**   0            0        0       0       3      

  AIS                   0               0          0        0       0         0        0       **0**        0        0       0       0      

  SCC                   1               0          0        0       0         4        2       0            **15**   0       0       25     

  ADC                   1               1          0        3       0         0        0       0            1        **2**   0       10     

  ADSQ                  0               0          0        0       0         0        0       0            0        1       **0**   1      

  Total                 4119            72         3        6       168       120      5       0            25       4       0       4522   
  -------------------------------------------------------------------------------------------------------------------------------------------------

NILM: negative for intraepithelial lesion or malignancy; ASC-US: atypical squamous cells of undetermined significance; ASC-H: atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; AGC: atypical glandular cells; LSIL: low-grade intraepithelial cells; HSIL: high-grade intraepithelial lesion; FSFI: HSIL features suspicious for invasion; AIS: adenocarcinoma in-situ; SCC: squamous cell carcinoma; ADC: adenocarcinoma; ADSQ: adenosquamous cell carcinoma.

###### 

Up-graded case by ThinPrep method.

  Conventional smear   ThinPrep                                                                            
  -------------------- ---------- -------- ------- ----- ------ ------ ------ --------- ------------------ --------
                       Number     ASC-US   ASC-H   AGC   LSIL   HSIL   FSFI   SCC/ADC   Up-grading by TP   
                                                                                                           
  NILM                 4062       35       1       1     33     7      0      0         77                 1.90%
  ASC-US               71         ---      ---     ---   10     2      0      0         12                 16.90%
  ASC-H                9          ---      ---     ---   2      1      1      0         4                  44.40%
  AGC                  8          ---      ---     ---   0      0      0      0         0                  ---
  LSIL                 221        ---      ---     ---   ---    27     0      0         27                 12.20%
  HSIL                 112        ---      ---     ---   ---    ---    2      5         7                  6.30%
  Total                4483       35       1       1     45     37     3      5         127                2.80%

###### 

Up-graded case by conventional smear method.

  ThinPrep   Conventional smear                                                                            
  ---------- -------------------- -------- ------- ----- ------ ------ ------ --------- ------------------ --------
             Number               ASC-US   ASC-H   AGC   LSIL   HSIL   FSFI   SCC/ADC   Up-grading by TP   
                                                                                                           
  NILM       4119                 47       2       5     73     5      0      2         134                3.30%
  ASC-US     72                   ---      ---     ---   17     4      0      1         22                 30.60%
  ASC-H      3                    ---      ---     ---   0      0      1      0         1                  33.30%
  AGC        6                    ---      ---     ---   0      0      0      3         3                  50.00%
  LSIL       168                  ---      ---     ---   ---    19     0      0         19                 11.30%
  HSIL       120                  ---      ---     ---   ---    ---    2      4         6                  5.00%
  Total      4488                 47       2       5     90     28     3      10        185                4.10%

###### 

Glandular abnormalities in TBS.

  Case   Age   CS        TP        HPV   Histology in cervical biopsy
  ------ ----- --------- --------- ----- -------------------------------------
  1      27    NILM      AGC       (−)   Endometrial pollyp
  2      38    AGC       NILM      56+   ND
  3      54    AGC       NILM      16+   Atypical endometrial hyperplasia^a^
  4      25    AGC       NILM      (−)   ND
  5      61    AGC       NILM      (−)   ND
  6      50    AGC       AGC       52+   Endometrioid adenoca, G2^a^
  7      36    AGC       AGC       16+   ND
  8      42    AGC       NILM      (−)   Mild glandular dysplasia
  9      74    AGC       ASC-US    (−)   clear cell carcinoma
  10     58    AdenoCa   AGC       (−)   ND
  11     40    AdenoCa   AdenoCa   (−)   Endometrioid adenoca, G1^a^
  12     65    AdenoCa   AGC       (−)   Endometrioid adenoca, G1\>G2^a^
  13     74    AdenoCa   AGC       (−)   Ovarian cancer^b^

^a^Disease existed in uterine corpus diagnosed in surgical samples.

^b^Diagnosed in surgical samples.
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